The Rosen Law Firm, P.A. announces that it is investigating potential
securities fraud claims against INSYS Therapeutics, Inc. (Nasdaq: INSY)
resulting from allegations that the Company may have issued materially
misleading business information to the investing public.
On December 12, 2013, the Company disclosed that it has received a
subpoena from the Office of Inspector General of the Department of
Health and Human Services (HHS) regarding an investigation of potential
violations involving HHS programs. The subpoena concerns Subsys®,
including INSYS' sales and marketing practices relating to this product.
On this news, shares of INSYS fell $7.56 per share, or by approximately
17%, during intraday trading on December 13, 2013.
The Rosen Law Firm is preparing a class action lawsuit as a result of
this adverse information. If you purchased INSYS securities, you may
visit the website at http://rosenlegal.com
to join the action. You may also contact Phillip Kim, Esq. or Jonathan
Horne, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via
e-mail at pkim@rosenlegal.com
or jhorne@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Copyright Business Wire 2013